Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
LaNova Medicines Limited
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06682780CT.gov A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours | — | Recruiting | — | — | — |
NCT06953323CT.gov A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05311579CT.gov Niraparib Plus Anlotinib for Recurrent Ovarian Cancer | — | Unknown | — | — | — |
NCT04991480CT.gov A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT04655183CT.gov Study of M4344 in Combination With Niraparib | — | Withdrawn | — | — | — |
NCT04502602CT.gov Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer | — | Active Not Recruiting | — | — | — |
NCT04170153CT.gov Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) | — | Active Not Recruiting | — | — | — |
NCT03497429CT.gov A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03307785CT.gov Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 | — | Completed | — | — | — |
NCT03221400CT.gov PEN-866 in Patients With Advanced Solid Malignancies | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Niraparib (this asset) | LaNova Medicines Limited | P2 | CCC · 52 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Propofol | Hong Kong Children's Hospital | P4 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P2/3 | BB |
| Anamorelin | Helsinn Healthcare SA | P3 | BB |
+42 more in the Cancer cohort
Other indications for Niraparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P3 | BB · 67 |
| Ovarian Carcinoma | — | P4 | BB · 66 |
| Ovarian Neoplasm | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Niraparib in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/niraparib-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →